IP Library Granted Patent US 12,092,637
Granted Patent B2
US 12,092,637 · App. 16/549,387 · Granted Sep 17, 2024

Method for measuring fibroblast growth factor-23 and reagent therefor

Inventors: Koji Uzawa (Shizuoka, JP); Emiko Suzuki (Shizuoka, JP); Kazuyuki Ikeda (Tokyo, JP); Kazuki Morita (Shizuoka, JP)
Assignee: HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO., LTD.
G01N33/54333G01N33/538G01N33/54326G01N33/74G01N2333/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,092,637
App. No.
16/549,387
Granted
Sep 17, 2024
Kind
B2
Abstract

A method for measuring fibroblast growth factor-23 (FGF-23) in a sample, which comprise the following steps: (1) reacting, in an aqueous medium, FGF-23 in a sample with magnetic particles, a first antibody or a fragment thereof which binds to FGF-23, and a second antibody or a fragment thereof which binds to FGF-23, to form on the magnetic particles an immunocomplex comprising the first antibody or a fragment thereof which binds to FGF-23. FGF-23, and the second antibody or a fragment thereof which binds to FGF-23; (2) collecting the magnetic particles in the reaction mixture after step (1) by magnetic force, and separating the magnetic particles collected by magnetic force from the other components; and (3) measuring the immunocomplex on the magnetic particles separated in step (2). The present invention provides a method for measuring FGF-23 in a sample, which have a high sensitivity and have a wide measurement range.

Claims (11)

1. A method for measuring fibroblast growth factor-23 (FGF-23) in a sample, wherein the method comprises the steps of:

(1) reacting, in an aqueous medium, FGF-23 in a sample with a magnetic particle bonded with a first antibody or a fragment thereof which binds to FGF-23, and a second antibody or a fragment thereof which binds to FGF-23, to form on the magnetic particle an immunocomplex comprising the first antibody or a fragment thereof which binds to FGF-23, FGF-23, and the second antibody or a fragment thereof which binds to FGF-23,

wherein the sample comprises FGF-23 in a concentration ranging from 5 pg/mL to 10,000 pg/mL;

(2) collecting the magnetic particle in the reaction mixture after step (1) by magnetic force, and separating the magnetic particle collected by magnetic force from the other components; and

(3) measuring the immunocomplex on the magnetic particle separated in step (2).

2. The method of claim 1 , wherein the second antibody is a labeled antibody.

3. The method of claim 2 , wherein the labeled antibody is an alkaline phosphatase-labeled antibody.

4. The method of claim 1 , wherein measurement of the immunocomplex on the magnetic particle in step (3) is carried out by measurement of chemiluminescence.

5. The method of claim 1 , wherein the sample is serum or plasma.

6. The method of claim 1 , wherein the sample comprises FGF-23 in a concentration ranging from 5 pg/mL to 3,000 pg/mL.

7. The method of claim 1 , wherein the sample comprises FGF-23 in a concentration ranging from 5 pg/mL to 1,000 pg/mL.

Assignments (3)
CHANGE OF NAME Recorded Sep 23, 2025
From: KYOWA MEDEX CO., LTD.
To: HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO., LTD.
Reel/Frame 072925/0508 →
CHANGE OF NAME Recorded Sep 23, 2025
From: HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO., LTD.
To: MINARIS MEDICAL CO., LTD.
Reel/Frame 072925/0657 →
CHANGE OF NAME Recorded Sep 23, 2025
From: MINARIS MEDICAL CO., LTD.
To: CANON MEDICAL DIAGNOSTICS CORPORATION
Reel/Frame 072925/0690 →
Priority Claims (1)
JP 2010-193213 · Aug 31, 2010 · national
Continuity (2)
Continuation 13819398
Related Publication 20190376961A1 · Dec 12, 2019